Embecta Corp (EMBC)vsMedline Inc. Class A Common Stock (MDLN)
EMBC
Embecta Corp
$9.00
-0.11%
HEALTHCARE · Cap: $526.47M
MDLN
Medline Inc. Class A Common Stock
$42.03
-1.06%
HEALTHCARE · Cap: $34.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 2533% more annual revenue ($28.43B vs $1.08B). EMBC leads profitability with a 12.9% profit margin vs 4.1%. EMBC trades at a lower P/E of 3.8x. EMBC earns a higher WallStSmart Score of 56/100 (C).
EMBC
Buy56
out of 100
Grade: C
MDLN
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+90.9%
Fair Value
$110.45
Current Price
$9.00
$101.45 discount
Margin of Safety
+32.7%
Fair Value
$66.92
Current Price
$42.03
$24.89 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Earnings expanding 82.7% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 29.2%
No standout strengths identified
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 0.3%
Moderate valuation
ROE of 6.5% — below average capital efficiency
4.1% margin — thin
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : EMBC
The strongest argument for EMBC centers on P/E Ratio, EPS Growth, Debt/Equity.
Bull Case : MDLN
Revenue growth of 14.8% demonstrates continued momentum.
Bear Case : EMBC
The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : MDLN
The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
EMBC profiles as a declining stock while MDLN is a value play — different risk/reward profiles.
MDLN is growing revenue faster at 14.8% — sustainability is the question.
EMBC generates stronger free cash flow (17M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
EMBC scores higher overall (56/100 vs 52/100). MDLN offers better value entry with a 32.7% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Embecta Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Embecta Corp (EMBC) is a leading global medical technology firm dedicated to advancing diabetes management through its cutting-edge insulin delivery solutions. As a spin-off from Becton, Dickinson and Company, Embecta leverages innovative technologies and a comprehensive product portfolio—including insulin pens and syringes—to enhance patient care and health outcomes. Committed to operational excellence and customer-centric strategies, the company is strategically positioned to capitalize on growth opportunities in the fast-evolving diabetes care market. With a focus on improving patient experiences, Embecta aims to drive sustainable development and solidify its leadership in the industry.
Visit Website →Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?